Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

The third quarter marked an important transition for Skye as a metabolic-focused company with the launch of our Phase 2 obesity clinical trial for nimacimab. We believe our truly ...

In a report released today, Albert Lowe from Craig-Hallum assigned a Buy rating to Skye Bioscience (SKYE – Research Report), with a price ...

Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report) shares were up 5.3% during trading on Wednesday .The company traded as high as $5.20 and last traded at $5.20. Approximately 168,072 shares ...

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for ...

Skye Bioscience ( (SKYE)) just unveiled an announcement. Skye Bioscience, Inc. held a special meeting where stockholders approved an amendment to increase the shares available under the 2014 ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic ...